Company Overview and News

23
EKSO / Ekso Bionics Holdings, Inc. 424B5 (Prospectus)

2018-07-10 sec.gov
Filed Pursuant to Rule 424(b)(5) Registration No. 333-218517 PROSPECTUS SUPPLEMENT (To Prospectus dated June 16, 2017)
EKSO

38
EKSO / Ekso Bionics Holdings, Inc. S-8

2018-07-02 sec.gov
As filed with the Securities and Exchange Commission on July 2, 2018 Registration No. 333-
EKSO

38
EKSO / Ekso Bionics Holdings, Inc. FORM 8-K (Current Report)

2018-06-12 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
EKSO

13
EKSO / Ekso Bionics Holdings, Inc. 8-K (Current Report)

2018-05-19 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
EKSO

10
Ekso Bionics Holdings' (EKSO) CEO Jack Peurach on Q1 2018 Results - Earnings Call Transcript

2018-05-08 seekingalpha
Greetings and welcome to the Ekso Bionics' First Quarter 2018 Financial Results Conference Call. As a reminder, this conference is being recorded.
EKSO

11
EKSO / Ekso Bionics Holdings, Inc. FORM 10-Q (Quarterly Report)

2018-05-07 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
EKSO

9
Ekso Bionics Reports First Quarter 2018 Results

2018-05-07 globenewswire
RICHMOND, Calif., May 07, 2018 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (NASDAQ:EKSO), an industry leader in exoskeleton technology for medical and industrial use, today reported financial results for the three months ended March 31, 2018.
EKSO

20
EKSO / Ekso Bionics Holdings, Inc. DEF 14A

2018-04-30 sec.gov
TABLE OF CONTENTS
EKSO

36
EKSO / Ekso Bionics Holdings, Inc. PRE 14A

2018-04-19 sec.gov
TABLE OF CONTENTS
EKSO

10
EKSO / Ekso Bionics Holdings, Inc. FORM 8-K (Current Report)

2018-03-28 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
EKSO

8
National Stroke Association and Ekso Bionics® Announce Educational Partnership to Advance Stroke Rehabilitation with Exoskeleton Technology

2018-03-27 globenewswire
CENTENNIAL, Colo., and RICHMOND, Calif., March 27, 2018 (GLOBE NEWSWIRE) -- National Stroke Association, a nonprofit that provides stroke education and programs to stroke survivors, caregivers, and the healthcare community, and Ekso Bionics Holdings, Inc. (NASDAQ:EKSO), an industry leader in exoskeleton technology for medical and industry use, today announced an educational partnership dedicated to increasing awareness of and access to advance stroke rehabilitation exoskeleton technology that enables earlier mobility and restored independence for survivors of stroke.
EKSO

9
EKSO / Ekso Bionics Holdings, Inc. FORM 10-K (Annual Report)

2018-03-13 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
EKSO

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Silicon Investor Message Boards

This table lists all message boards related to EKSO / Ekso Bionics Holdings, Inc. on message board site Silicon Investor.

EKSO Bio
CUSIP: 282644202